Jean‐Baptiste Telliez

Publications by Year

Research Areas

Cytokine Signaling Pathways and Interactions, Protein Kinase Regulation and GTPase Signaling, Melanoma and MAPK Pathways, NF-κB Signaling Pathways, Rheumatoid Arthritis Research and Therapies

Most-Cited Works

• → Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases(2014)581 cited
• The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.(2016)
• → Parsing the Interferon Transcriptional Network and Its Disease Associations(2016)341 cited
• → Distinct Cellular Functions of MK2(2002)234 cited
• → The Mitogen-Activated Protein Kinase (MAPK)-Activated Protein Kinases MK2 and MK3 Cooperate in Stimulation of Tumor Necrosis Factor Biosynthesis and Stabilization of p38 MAPK(2006)219 cited
• → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)189 cited
• → JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines(2015)172 cited
• → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
• → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited
• → Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans(2017)160 cited